Anteris reports no moderate or severe prosthesis-patient mismatch at 30 days in medium-size DurAVR study
AVR•Anteris Technologies reported 30-day results from 22 patients in its medium-size DurAVR study, with no valve-related deaths, moderate or severe leakage, or moderate or severe prosthesis-patient mismatch.
1. Study results
Anteris Technologies reported 30-day results for its medium-size DurAVR transcatheter heart valve in 22 patients with severe aortic stenosis and medium-sized aortic annuli. Presented at the TCT 2026 conference in San Diego, the results showed favorable blood-flow performance, with no valve-related deaths, moderate or severe leakage, or moderate or severe prosthesis-patient mismatch. The ongoing PARADIGM pivotal trial is enrolling patients to compare DurAVR with commercially available replacement valves and will include the medium-size device.
